Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Xilio Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
XLO
Nasdaq
8731
https://xiliotx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Xilio Therapeutics Inc
Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
- Apr 16th, 2024 1:14 pm
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
- Apr 1st, 2024 8:05 pm
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
- Mar 28th, 2024 11:05 am
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
- Mar 28th, 2024 11:00 am
Gilead bets on Xilio cancer drug as biotech restructures
- Mar 28th, 2024 10:45 am
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
- Feb 28th, 2024 9:01 pm
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
- Jan 31st, 2024 9:01 pm
Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies
- Jan 8th, 2024 12:30 pm
Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data
- Dec 7th, 2023 12:30 pm
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results
- Nov 9th, 2023 9:01 pm
Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors
- Nov 3rd, 2023 4:00 pm
Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting
- Oct 31st, 2023 1:15 pm
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Sep 27th, 2023 9:02 pm
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer
- Sep 5th, 2023 12:30 pm
Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
- Sep 5th, 2023 11:30 am
Q2 2023 Xilio Therapeutics Inc Earnings Call
- Aug 18th, 2023 8:27 am
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results
- Aug 14th, 2023 11:30 am
Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer
- Aug 3rd, 2023 8:05 pm
Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors
- May 25th, 2023 9:01 pm
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results
- May 9th, 2023 11:30 am
Scroll